show help

Arnold E

Author page

This page provides a summary of the entries in Polbase associated with this author.

The publication history graph presents the number of publications in Polbase by this author over time.

The polymerase chart indicates which polymerases this author has published on.

Polbase automatically discovers many polymerase papers as they are published. Some relevant papers are not included because the algorithm is designed to reduce background. Please contribute to polbase by adding your missing DNA polymerase papers.

Help icons:

The show help symbol in the upper-right corner of the page links to this help text. The question mark icon is used everywhere to indicate that help is available.

Missing references?

Publications:

Title Authors Year Journal
On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data. Arnold E Journal of computer-aided molecular design
HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Arnold E 2013 Current opinion in virology
HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Arnold E 2013 Current opinion in virology
Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase. Arnold E 2013 Nature chemistry
Molecular dynamics study of HIV-1 RT-DNA-Nevirapine complexes explains NNRTI inhibition, and resistance by connection mutations. Arnold E 2013 Proteins
Extension into the entrance channel of HIV-1 reverse transcriptase-Crystallography and enhanced solubility. Arnold E 2013 Bioorganic & medicinal chemistry letters
Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening. Arnold E 2013 Journal of medicinal chemistry
HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Arnold E 2012 Nature structural & molecular biology
A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants. Arnold E 2012 Retrovirology
Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. Arnold E 2011 Journal of medicinal chemistry
Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies. Arnold E 2011 Journal of chemical information and modeling
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. Arnold E 2011 Journal of medicinal chemistry
Fragment Screening and HIV Therapeutics. Arnold E 2011 Topics in current chemistry
Structural basis of HIV-1 resistance to AZT by excision. Arnold E 2010 Nature structural & molecular biology
Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. Arnold E 2009 The Journal of biological chemistry
Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures. Arnold E 2009 Journal of medicinal chemistry
Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions. Arnold E 2009 Journal of virology
Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase. Arnold E 2009 J Med Chem
Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Arnold E 2009 Structure (London, England : 1993)
Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. Arnold E 2009 Journal of molecular biology
2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Arnold E 2008 The international journal of biochemistry & cell biology
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Arnold E 2008 Nucleic acids research
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Arnold E 2008 Proceedings of the National Academy of Sciences of the United States of America
Two-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase. Arnold E 2008 Proceedings of the National Academy of Sciences of the United States of America
3'-Azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase. Arnold E 2007 Biochemistry
Synthesis of AZTpSpCX2ppSA and AZTpSpCX2ppSAZT: hydrolysis-resistant potential inhibitors of the AZT excision reaction of HIV-1 RT. Arnold E 2007 Organic letters
Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. Arnold E 2007 Journal of medicinal chemistry
Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. Arnold E 2007 Journal of molecular biology
Combining mutations in HIV-1 reverse transcriptase with mutations in the HIV-1 polypurine tract affects RNase H cleavages involved in PPT utilization. Arnold E 2006 Virology
Structural determinants of slippage-mediated mutations by human immunodeficiency virus type 1 reverse transcriptase. Arnold E 2006 The Journal of biological chemistry
Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? Arnold E 2006 PLoS Pathog
HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. Arnold E 2006 ACS Chem Biol
4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains. Arnold E 2005 Journal of medicinal chemistry
Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. Arnold E 2005 J Med Chem
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. Arnold E 2005 J Med Chem
Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions. Arnold E 2005 Journal of molecular biology
Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Arnold E 2005 Progress in biophysics and molecular biology
Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. Arnold E 2005 Journal of medicinal chemistry
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). Arnold E 2005 J Med Chem
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. Arnold E 2005 Journal of medicinal chemistry
Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo. Arnold E 2004 J Virol
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Arnold E 2004 Nature structural & molecular biology
Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs. Arnold E 2004 Int J Biochem Cell Biol
Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds. Arnold E 2004 Drugs in R&D
Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. Arnold E 2004 J Virol
Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Arnold E 2004 Current opinion in structural biology
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. Arnold E 2004 J Med Chem
Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA. Arnold E 2004 J Virol
Effects of mutations in the G tract of the human immunodeficiency virus type 1 polypurine tract on virus replication and RNase H cleavage. Arnold E 2004 J Virol
Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues. Arnold E 2003 Journal of medicinal chemistry
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. Arnold E 2003 Journal of virology
Mutations in the 5' end of the human immunodeficiency virus type 1 polypurine tract affect RNase H cleavage specificity and virus titer. Arnold E 2003 J Virol
HIV-1 reverse transcriptase variants: molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method. Arnold E 2003 Drug design and discovery
Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Arnold E 2003 Nucleic acids research
Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. Arnold E 2003 J Virol
Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. Arnold E 2003 Biophysical journal
A novel mechanism for inhibition of HIV-1 reverse transcriptase. Arnold E 2002 Bioorganic chemistry
Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. Arnold E 2002 The EMBO journal
The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. Arnold E 2002 J Virol
Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. Arnold E 2002 Proceedings of the National Academy of Sciences of the United States of America
Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. Arnold E 2002 J Virol
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. Arnold E 2001 Journal of molecular biology
Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. Arnold E 2001 J Virol
RNase H cleavage of the 5' end of the human immunodeficiency virus type 1 genome. Arnold E 2001 J Virol
Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. Arnold E 2001 The EMBO journal
HIV-1 reverse transcriptase mutations found in a drug-experienced patient confer reduced susceptibility to multiple nucleoside reverse transcriptase inhibitors. Arnold E 2001 Antiviral therapy
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Arnold E 2001 Bioorganic & medicinal chemistry letters
Molecular dynamics of HIV-1 reverse transcriptase indicates increased flexibility upon DNA binding. Arnold E 2001 Proteins
Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. Arnold E 2001 Bioorganic & medicinal chemistry letters
Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Arnold E 2001 Proceedings of the National Academy of Sciences of the United States of America
Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). Arnold E 2001 Bioorganic & medicinal chemistry letters
Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). Arnold E 2001 J Virol
YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro. Arnold E 2001 J Virol
Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase. Arnold E 2000 Proceedings of the National Academy of Sciences of the United States of America
The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. Arnold E 2000 Journal of molecular biology
Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Arnold E 1999 Proceedings of the National Academy of Sciences of the United States of America
Similarities and differences in the RNase H activities of human immunodeficiency virus type 1 reverse transcriptase and Moloney murine leukemia virus reverse transcriptase. Arnold E 1999 Journal of molecular biology
Major subdomain rearrangement in HIV-1 reverse transcriptase simulated by molecular dynamics. Arnold E 1999 Proteins
Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Arnold E 1999 Chemistry & biology
Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase. Arnold E 1998 Journal of molecular biology
Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. Arnold E 1998 Journal of molecular biology
Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. Arnold E 1998 Journal of molecular biology
Protein-nucleic acid interactions and DNA conformation in a complex of human immunodeficiency virus type 1 reverse transcriptase with a double-stranded DNA template-primer. Arnold E 1997 Biopolymers
Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Arnold E 1996 Drug design and discovery
Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants. Arnold E 1996 Proceedings of the National Academy of Sciences of the United States of America
Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors. Arnold E 1996 Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine. Arnold E 1996 Journal of virology
Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. Arnold E 1996 Journal of molecular biology
Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Arnold E 1996 Structure (London, England : 1993)
Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. Arnold E 1995 Biochemistry
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Arnold E 1995 Proceedings of the National Academy of Sciences of the United States of America
Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Arnold E 1995 Protein science : a publication of the Protein Society
An expanded model of replicating human immunodeficiency virus reverse transcriptase. Arnold E 1995 Biochemistry
Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors, and an antibody Fab fragment. Arnold E 1995 Methods in enzymology
Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Arnold E 1995 Nat Struct Biol
Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates. Arnold E 1995 Current opinion in structural biology
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Arnold E 1995 Antimicrob Agents Chemother
Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. Arnold E 1994 Journal of molecular biology
A computer-assisted analysis of conserved residues in the three-dimensional structures of the polymerase domains of Escherichia coli DNA polymerase I and HIV-1 reverse transcriptase. Arnold E 1994 The Journal of biological chemistry
Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase. Arnold E 1994 Journal of molecular biology
Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Arnold E 1994 Proceedings of the National Academy of Sciences of the United States of America
Identification of a pharmacophore for nucleoside analog inhibitors directed at HIV-1 reverse transcriptase. Arnold E 1994 Journal of molecular recognition : JMR
Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Arnold E 1994 Antimicrobial agents and chemotherapy
Buried surface analysis of HIV-1 reverse transcriptase p66/p51 heterodimer and its interaction with dsDNA template/primer. Arnold E 1994 Journal of molecular recognition : JMR
Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations. Arnold E 1992 Nature
Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody Fab fragment and double-stranded DNA diffract x-rays to 3.5-A resolution. Arnold E 1991 Proceedings of the National Academy of Sciences of the United States of America
HIV reverse transcriptase structure-function relationships. Arnold E 1991 Biochemistry

Using Polbase tables:

Sorting:

Tables may be sorted by clicking on any of the column titles. A second click reverses the sort order. <Ctrl> + click on the column titles to sort by more than one column (e.g. family then name).

Filtering:

It is also possible to filter the table by typing into the search box above the table. This will instantly hide lines from the table that do not contain your search text.